Close Menu

NEW YORK (GenomeWeb) – Gurgaon, India-based Core Diagnostics said today that it has reached an agreement with Guardant Health AMEA under which it will market Guardant's comprehensive liquid biopsy test, Guardant360, in India.

Guardant360 detects cell-free circulating tumor DNA from 73 genes in blood samples from advanced solid-tumor cancer patients, detecting the four major classes of alterations relevant for treatment selection: point mutations, indels, copy number alteration, and fusions/rearrangements.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.